Annamaria Naggi

Author PubWeight™ 39.08‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 2008 4.46
2 Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des 2007 2.14
3 Generation of "neoheparin" from E. coli K5 capsular polysaccharide. J Med Chem 2005 2.03
4 The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 2007 1.49
5 SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res 2011 1.40
6 Orthogonal analytical approaches to detect potential contaminants in heparin. Proc Natl Acad Sci U S A 2009 1.36
7 Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models. FASEB J 2005 1.32
8 The impact of heparanese and heparin on cancer metastasis and angiogenesis. Pathophysiol Haemost Thromb 2006 1.29
9 Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer. Matrix Biol 2010 1.21
10 P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. FASEB J 2007 1.14
11 Complex glycosaminoglycans: profiling substitution patterns by two-dimensional nuclear magnetic resonance spectroscopy. Anal Biochem 2005 1.09
12 Low molecular weight heparins: structural differentiation by bidimensional nuclear magnetic resonance spectroscopy. Semin Thromb Hemost 2007 1.08
13 Structural features of low-molecular-weight heparins affecting their affinity to antithrombin. Thromb Haemost 2009 1.06
14 Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo. Blood 2014 1.03
15 Undersulfated and glycol-split heparins endowed with antiangiogenic activity. J Med Chem 2004 0.99
16 Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors. Biochemistry 2002 0.96
17 Heparanase, heparin and the coagulation system in cancer progression. Thromb Res 2007 0.95
18 The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives. Thromb Res 2011 0.89
19 Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist. Glycobiology 2004 0.87
20 Chemical derivatization as a strategy to study structure-activity relationships of glycosaminoglycans. Semin Thromb Hemost 2002 0.86
21 Profiling glycol-split heparins by high-performance liquid chromatography/mass spectrometry analysis of their heparinase-generated oligosaccharides. Anal Biochem 2012 0.85
22 Minimal heparin/heparan sulfate sequences for binding to fibroblast growth factor-1. Biochem Biophys Res Commun 2002 0.84
23 Active conformations of glycosaminoglycans. NMR determination of the conformation of heparin sequences complexed with antithrombin and fibroblast growth factors in solution. Semin Thromb Hemost 2002 0.82
24 Characterizing the microstructure of heparin and heparan sulfate using N-sulfoglucosamine 1H and 15N NMR chemical shift analysis. Anal Chem 2012 0.82
25 The tainted heparin story: an update. Thromb Haemost 2009 0.82
26 High-performance liquid chromatographic/mass spectrometric studies on the susceptibility of heparin species to cleavage by heparanase. Semin Thromb Hemost 2007 0.80
27 Insights into the human glycan receptor conformation of 1918 pandemic hemagglutinin-glycan complexes derived from nuclear magnetic resonance and molecular dynamics studies. Biochemistry 2014 0.79
28 Glycosaminoglycans inhibit the adherence and the spreading of osteoclasts and their precursors: role in osteoclastogenesis and bone resorption. Eur J Cell Biol 2010 0.79
29 Interactions of low-molecular-weight semi-synthetic sulfated heparins with human leukocyte elastase and human Cathepsin G. Biochem Pharmacol 2005 0.79
30 Structural features of glycol-split low-molecular-weight heparins and their heparin lyase generated fragments. Anal Bioanal Chem 2013 0.78
31 O-sulfated bacterial polysaccharides with low anticoagulant activity inhibit metastasis. Semin Thromb Hemost 2007 0.78
32 Reversed-phase ion-pair ultra-high-performance-liquid chromatography-mass spectrometry for fingerprinting low-molecular-weight heparins. J Chromatogr A 2013 0.77
33 Modulation of antithrombin-protease interactions by semisynthetic low-molecular-weight heparins with different sulfation patterns. Semin Thromb Hemost 2003 0.76
34 Inhibitory effects of glycosaminoglycans on basal and stimulated transforming growth factor-β1 expression in mesangial cells: biochemical and structural considerations. Glycobiology 2011 0.75
35 Electrochemical characterisation of 6-iodomaltose, 6'-iodomaltose and 6-iodomaltotriose on a silver cathode and their one-pot electrochemical dimerisation to new mixed O/C maltotetraose and maltohexaose mimics. Chemistry 2009 0.75
36 Inhibition of B16-BL6 melanoma lung colonies by semisynthetic sulfaminoheparosan sulfates from E. coli K5 polysaccharide. Semin Thromb Hemost 2002 0.75
37 Effects of calcium ions on the interactions between antithrombin and factor Xa mediated by variously sulfated, semisynthetic low-molecular-weight heparins. Semin Thromb Hemost 2002 0.75
38 Low-molecular-weight heparin and dermatan sulfate end group-labeled with tyramine and fluorescein. Biochemical and biological characterization of the fluorescent-labeled heparin derivative. Semin Thromb Hemost 2002 0.75
39 Structure of a heteroxylan of gum exudate of the palm Scheelea phalerata (uricuri). Phytochemistry 2004 0.75